Labcorp Declares $0.72 Quarterly Dividend, Attracting Income Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 10 2024
0mins
Should l Buy LH?
Source: Newsfilter
Labcorp Holdings Inc's stock has hit a 20-day low, declining by 4.56% in regular trading.
The company has declared a quarterly dividend of $0.72 per share, consistent with previous payouts, indicating stable cash flow and profitability, which is likely to attract more income-focused investors. Additionally, Labcorp anticipates a 5.4% midpoint revenue growth and a 9% EPS target for 2026, demonstrating its strategic commitment to advancing specialty and AI initiatives.
This dividend declaration not only rewards shareholders but also boosts investor confidence, potentially stabilizing the stock price in a challenging market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 270.680
Low
270.00
Averages
304.45
High
325.00
Current: 270.680
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp Launches First FDA-Cleared Rapid Fentanyl Urine Test
- Rapid Testing Innovation: Labcorp's Fentanyl Urine Visual Test is the first FDA-cleared rapid test in the U.S., delivering results in just 10 minutes, enabling healthcare providers to respond swiftly to suspected fentanyl exposure in emergency departments, hospitals, and clinics.
- Market Demand Response: Labcorp data indicates that between 2024 and 2025, approximately 4% of pre-employment screenings tested positive for fentanyl, and nearly 10% of patients undergoing opioid use disorder treatment also tested positive, highlighting the urgent need for reliable screening tools as synthetic opioids become more prevalent.
- Detection Window Advantage: The test assesses fentanyl exposure by detecting norfentanyl, the primary metabolite, which can remain in urine for up to 48 hours after initial exposure, providing a longer detection window than fentanyl itself, thereby enhancing clinical decision-making effectiveness.
- Clinical Application Support: Dr. Brian Caveney, Labcorp's Chief Medical and Scientific Officer, emphasizes that the test provides clinicians with quick, dependable answers, ultimately supporting better patient outcomes and reflecting the company's commitment to innovative testing tools in emergency and clinical settings.
See More
Labcorp Launches First FDA-Cleared Rapid Fentanyl Test in the U.S.
- Rapid Testing Innovation: Labcorp's Fentanyl Urine Visual Test is the first FDA-cleared rapid test in the U.S., delivering results in just 10 minutes, thereby enabling emergency departments and hospitals to respond swiftly to suspected fentanyl exposure, significantly enhancing patient care efficiency.
- Market Demand Response: Labcorp's data indicates that between 2024 and 2025, approximately 4% of pre-employment screenings tested positive for fentanyl, and nearly 10% of patients undergoing opioid use disorder treatment tested positive, highlighting the urgent need for rapid and reliable screening tools, especially as synthetic opioids become more prevalent.
- Detection Window Advantage: The test detects norfentanyl, the primary metabolite, providing a longer detection window than fentanyl itself, which may clear within hours, thus offering clinicians a more reliable diagnostic basis to support better patient outcomes.
- Brand Transformation: The Labcorp Fentanyl Urine Visual Test is available through Labcorp Point of Care, marking a transition from the MEDTOX Diagnostics brand, with a complete overhaul of product names, packaging, and resources expected throughout 2026, further enhancing brand recognition and market impact.
See More
Labcorp Launches AI-Powered Real-World Data Platform for Alzheimer's Research
- Platform Innovation: Labcorp, in collaboration with AWS and Datavant, has launched an AI-powered real-world data platform aimed at accelerating the analysis of Alzheimer's disease-related data, enabling researchers to generate insights in minutes that previously took months, thereby significantly shortening drug development timelines.
- Data Integration Advantage: The platform integrates standardized laboratory data from millions of patients and leverages advanced AI models to streamline data access and analysis, addressing the challenges of traditional data fragmentation and lengthy preparation times, thus enhancing research efficiency.
- Clinical Trial Recruitment Optimization: By quickly identifying patient cohorts and tracking disease progression, the platform supports the selection of suitable de-identified patient cohorts for clinical trial recruitment based on defined inclusion and exclusion criteria, thereby increasing the success rate of clinical research.
- Future Expansion Plans: The platform is expected to complete its initial validation phase in 2026 and will expand to include inflammatory diseases, cardiometabolic conditions, women's health, and oncology, further accelerating research insights and demonstrating Labcorp's leadership in real-world data strategy.
See More
Labcorp and CHOP Collaborate to Advance Pediatric Diagnostics
- Strategic Collaboration: Labcorp and Children's Hospital of Philadelphia (CHOP) announced a partnership aimed at accelerating the discovery and development of specialized pediatric diagnostics, combining CHOP's research expertise with Labcorp's national diagnostic infrastructure to enhance access for children and families, which is expected to significantly improve children's health outcomes.
- Innovation Pipeline Creation: The collaboration will establish a joint pediatric diagnostics innovation pipeline focused on developing new tests and technologies, streamlining the path from discovery to national availability, ensuring that novel diagnostics can serve children more rapidly, particularly in critical areas such as oncology and metabolic diseases.
- Enhanced Nationwide Access: Together, Labcorp and CHOP will provide cutting-edge pediatric testing to clinicians and health systems, enabling breakthrough diagnostics in cancer, genetics, and immune disorders to reach patients sooner, thereby facilitating earlier and more accurate diagnoses.
- Advancing Scientific Research: This partnership marks a significant milestone at the intersection of scientific research and collaboration, with Labcorp and CHOP committed to accelerating pediatric diagnostic innovations aimed at improving the quality of life for children, demonstrating a strong commitment to the future of pediatric healthcare.
See More
Labcorp and Children's Hospital Collaborate to Advance Pediatric Diagnostics
- Strategic Collaboration: Labcorp and the Children's Hospital of Philadelphia (CHOP) announced a strategic partnership aimed at accelerating the discovery and development of specialized pediatric diagnostics, enhancing access to health services for children by leveraging CHOP's research expertise and Labcorp's national diagnostic infrastructure.
- Innovation Pipeline: The collaboration will establish a pediatric diagnostics innovation pipeline focused on developing new tests and technologies, with the goal of streamlining the path from discovery to national availability, addressing the unique biological and physiological needs of children.
- Nationwide Testing Access: Together, the organizations will enable clinicians and health systems to access breakthrough pediatric testing in areas such as cancer, genetics, immune disorders, and rare diseases more quickly, facilitating earlier and more accurate diagnoses that significantly improve health outcomes for children.
- Advancing Scientific Research: This partnership marks a pivotal intersection of scientific research and clinical practice, as the collaboration between Labcorp and CHOP aims to drive innovation in pediatric care, committed to providing better healthcare solutions for children and their families.
See More
LH Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: LH's stock has a 52-week low of $209.375 and a high of $293.72, with the last trade at $260.61, indicating significant price movement within this range and reflecting market interest and investor sentiment changes.
- Technical Analysis Reference: Data from TechnicalAnalysisChannel.com highlights the relationship between LH's stock performance and its 200-day moving average, allowing investors to assess its short-term and long-term investment value for more precise strategy formulation.
- Market Sentiment Impact: The current stock price of $260.61, close to the 52-week low, may raise investor concerns about future trends, particularly amid increased market volatility, potentially affecting buying decisions and holding confidence.
- Investor Focus: The high and low data for LH's stock provides crucial reference points for investors, aiding in decision-making by considering market trends and potential risks to optimize their investment portfolios.
See More
Labcorp Launches First FDA-Cleared Rapid Fentanyl Urine Test
- Rapid Testing Innovation: Labcorp's Fentanyl Urine Visual Test is the first FDA-cleared rapid test in the U.S., delivering results in just 10 minutes, enabling healthcare providers to respond swiftly to suspected fentanyl exposure in emergency departments, hospitals, and clinics.
- Market Demand Response: Labcorp data indicates that between 2024 and 2025, approximately 4% of pre-employment screenings tested positive for fentanyl, and nearly 10% of patients undergoing opioid use disorder treatment also tested positive, highlighting the urgent need for reliable screening tools as synthetic opioids become more prevalent.
- Detection Window Advantage: The test assesses fentanyl exposure by detecting norfentanyl, the primary metabolite, which can remain in urine for up to 48 hours after initial exposure, providing a longer detection window than fentanyl itself, thereby enhancing clinical decision-making effectiveness.
- Clinical Application Support: Dr. Brian Caveney, Labcorp's Chief Medical and Scientific Officer, emphasizes that the test provides clinicians with quick, dependable answers, ultimately supporting better patient outcomes and reflecting the company's commitment to innovative testing tools in emergency and clinical settings.
See More
Labcorp Launches First FDA-Cleared Rapid Fentanyl Test in the U.S.
- Rapid Testing Innovation: Labcorp's Fentanyl Urine Visual Test is the first FDA-cleared rapid test in the U.S., delivering results in just 10 minutes, thereby enabling emergency departments and hospitals to respond swiftly to suspected fentanyl exposure, significantly enhancing patient care efficiency.
- Market Demand Response: Labcorp's data indicates that between 2024 and 2025, approximately 4% of pre-employment screenings tested positive for fentanyl, and nearly 10% of patients undergoing opioid use disorder treatment tested positive, highlighting the urgent need for rapid and reliable screening tools, especially as synthetic opioids become more prevalent.
- Detection Window Advantage: The test detects norfentanyl, the primary metabolite, providing a longer detection window than fentanyl itself, which may clear within hours, thus offering clinicians a more reliable diagnostic basis to support better patient outcomes.
- Brand Transformation: The Labcorp Fentanyl Urine Visual Test is available through Labcorp Point of Care, marking a transition from the MEDTOX Diagnostics brand, with a complete overhaul of product names, packaging, and resources expected throughout 2026, further enhancing brand recognition and market impact.
See More
Labcorp Launches AI-Powered Real-World Data Platform for Alzheimer's Research
- Platform Innovation: Labcorp, in collaboration with AWS and Datavant, has launched an AI-powered real-world data platform aimed at accelerating the analysis of Alzheimer's disease-related data, enabling researchers to generate insights in minutes that previously took months, thereby significantly shortening drug development timelines.
- Data Integration Advantage: The platform integrates standardized laboratory data from millions of patients and leverages advanced AI models to streamline data access and analysis, addressing the challenges of traditional data fragmentation and lengthy preparation times, thus enhancing research efficiency.
- Clinical Trial Recruitment Optimization: By quickly identifying patient cohorts and tracking disease progression, the platform supports the selection of suitable de-identified patient cohorts for clinical trial recruitment based on defined inclusion and exclusion criteria, thereby increasing the success rate of clinical research.
- Future Expansion Plans: The platform is expected to complete its initial validation phase in 2026 and will expand to include inflammatory diseases, cardiometabolic conditions, women's health, and oncology, further accelerating research insights and demonstrating Labcorp's leadership in real-world data strategy.
See More
Labcorp and CHOP Collaborate to Advance Pediatric Diagnostics
- Strategic Collaboration: Labcorp and Children's Hospital of Philadelphia (CHOP) announced a partnership aimed at accelerating the discovery and development of specialized pediatric diagnostics, combining CHOP's research expertise with Labcorp's national diagnostic infrastructure to enhance access for children and families, which is expected to significantly improve children's health outcomes.
- Innovation Pipeline Creation: The collaboration will establish a joint pediatric diagnostics innovation pipeline focused on developing new tests and technologies, streamlining the path from discovery to national availability, ensuring that novel diagnostics can serve children more rapidly, particularly in critical areas such as oncology and metabolic diseases.
- Enhanced Nationwide Access: Together, Labcorp and CHOP will provide cutting-edge pediatric testing to clinicians and health systems, enabling breakthrough diagnostics in cancer, genetics, and immune disorders to reach patients sooner, thereby facilitating earlier and more accurate diagnoses.
- Advancing Scientific Research: This partnership marks a significant milestone at the intersection of scientific research and collaboration, with Labcorp and CHOP committed to accelerating pediatric diagnostic innovations aimed at improving the quality of life for children, demonstrating a strong commitment to the future of pediatric healthcare.
See More
Labcorp and Children's Hospital Collaborate to Advance Pediatric Diagnostics
- Strategic Collaboration: Labcorp and the Children's Hospital of Philadelphia (CHOP) announced a strategic partnership aimed at accelerating the discovery and development of specialized pediatric diagnostics, enhancing access to health services for children by leveraging CHOP's research expertise and Labcorp's national diagnostic infrastructure.
- Innovation Pipeline: The collaboration will establish a pediatric diagnostics innovation pipeline focused on developing new tests and technologies, with the goal of streamlining the path from discovery to national availability, addressing the unique biological and physiological needs of children.
- Nationwide Testing Access: Together, the organizations will enable clinicians and health systems to access breakthrough pediatric testing in areas such as cancer, genetics, immune disorders, and rare diseases more quickly, facilitating earlier and more accurate diagnoses that significantly improve health outcomes for children.
- Advancing Scientific Research: This partnership marks a pivotal intersection of scientific research and clinical practice, as the collaboration between Labcorp and CHOP aims to drive innovation in pediatric care, committed to providing better healthcare solutions for children and their families.
See More
LH Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: LH's stock has a 52-week low of $209.375 and a high of $293.72, with the last trade at $260.61, indicating significant price movement within this range and reflecting market interest and investor sentiment changes.
- Technical Analysis Reference: Data from TechnicalAnalysisChannel.com highlights the relationship between LH's stock performance and its 200-day moving average, allowing investors to assess its short-term and long-term investment value for more precise strategy formulation.
- Market Sentiment Impact: The current stock price of $260.61, close to the 52-week low, may raise investor concerns about future trends, particularly amid increased market volatility, potentially affecting buying decisions and holding confidence.
- Investor Focus: The high and low data for LH's stock provides crucial reference points for investors, aiding in decision-making by considering market trends and potential risks to optimize their investment portfolios.
See More
